BIOGEN INC (BIIB) Stock Fundamental Analysis
USA - NASDAQ:BIIB - US09062X1037 - Common Stock
149.61 USD
-1.36 (-0.9%)
149.62 USD
+0.01 (+0.01%)
Taking everything into account, BIIB scores 5 out of 10 in our fundamental rating. BIIB was compared to 536 industry peers in the Biotechnology industry. BIIB scores excellent on profitability, but there are some minor concerns on its financial health. BIIB is cheap, but on the other hand it scores bad on growth. With these ratings, BIIB could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
BIIB had positive earnings in the past year.
BIIB had a positive operating cash flow in the past year.
In the past 5 years BIIB has always been profitable.
BIIB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIIB has a Return On Assets of 5.40%. This is amongst the best in the industry. BIIB outperforms 91.79% of its industry peers.
BIIB has a Return On Equity of 8.68%. This is amongst the best in the industry. BIIB outperforms 92.91% of its industry peers.
The Return On Invested Capital of BIIB (9.52%) is better than 94.22% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIIB is below the industry average of 15.47%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROIC | 9.52% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
BIIB's Profit Margin of 15.31% is amongst the best of the industry. BIIB outperforms 93.66% of its industry peers.
In the last couple of years the Profit Margin of BIIB has declined.
Looking at the Operating Margin, with a value of 27.35%, BIIB belongs to the top of the industry, outperforming 96.27% of the companies in the same industry.
In the last couple of years the Operating Margin of BIIB has declined.
BIIB's Gross Margin of 75.43% is amongst the best of the industry. BIIB outperforms 83.40% of its industry peers.
BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BIIB is creating some value.
The number of shares outstanding for BIIB has been increased compared to 1 year ago.
BIIB has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BIIB has an improved debt to assets ratio.
2.2 Solvency
BIIB has an Altman-Z score of 3.11. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.11, BIIB is in the better half of the industry, outperforming 69.03% of the companies in the same industry.
BIIB has a debt to FCF ratio of 3.40. This is a good value and a sign of high solvency as BIIB would need 3.40 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 3.40, BIIB belongs to the best of the industry, outperforming 93.84% of the companies in the same industry.
A Debt/Equity ratio of 0.36 indicates that BIIB is not too dependend on debt financing.
BIIB's Debt to Equity ratio of 0.36 is on the low side compared to the rest of the industry. BIIB is outperformed by 70.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Altman-Z | 3.11 |
ROIC/WACC1.04
WACC9.19%
2.3 Liquidity
BIIB has a Current Ratio of 2.50. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
BIIB has a worse Current ratio (2.50) than 68.84% of its industry peers.
BIIB has a Quick Ratio of 1.79. This is a normal value and indicates that BIIB is financially healthy and should not expect problems in meeting its short term obligations.
BIIB has a worse Quick ratio (1.79) than 77.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
The earnings per share for BIIB have decreased by -3.61% in the last year.
The earnings per share for BIIB have been decreasing by -13.31% on average. This is quite bad
The Revenue has been growing slightly by 3.36% in the past year.
Measured over the past years, BIIB shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
3.2 Future
Based on estimates for the next years, BIIB will show a small growth in Earnings Per Share. The EPS will grow by 1.15% on average per year.
BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.44% yearly.
EPS Next Y-1.72%
EPS Next 2Y-1.05%
EPS Next 3Y0.57%
EPS Next 5Y1.15%
Revenue Next Year0.4%
Revenue Next 2Y-1.8%
Revenue Next 3Y-1.14%
Revenue Next 5Y-0.44%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.34, the valuation of BIIB can be described as reasonable.
BIIB's Price/Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.57% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.70. BIIB is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 9.28, the valuation of BIIB can be described as very reasonable.
Based on the Price/Forward Earnings ratio, BIIB is valued cheaply inside the industry as 97.76% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of BIIB to the average of the S&P500 Index (23.15), we can say BIIB is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.34 | ||
| Fwd PE | 9.28 |
4.2 Price Multiples
97.57% of the companies in the same industry are more expensive than BIIB, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, BIIB is valued cheaply inside the industry as 97.76% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.88 | ||
| EV/EBITDA | 7.38 |
4.3 Compensation for Growth
BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.05%
EPS Next 3Y0.57%
5. Dividend
5.1 Amount
BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
149.61
-1.36 (-0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner Change0%
Ins Owners0.14%
Ins Owner Change3.4%
Market Cap21.93B
Analysts73.81
Price Target173.2 (15.77%)
Short Float %3.5%
Short Ratio3.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.1%
Min EPS beat(2)17.28%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)15.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)13.06%
EPS beat(12)12
Avg EPS beat(12)11.49%
EPS beat(16)14
Avg EPS beat(16)10.96%
Revenue beat(2)2
Avg Revenue beat(2)9.15%
Min Revenue beat(2)6.67%
Max Revenue beat(2)11.62%
Revenue beat(4)3
Avg Revenue beat(4)4.43%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)1.84%
Revenue beat(12)8
Avg Revenue beat(12)1.78%
Revenue beat(16)11
Avg Revenue beat(16)1.73%
PT rev (1m)0.78%
PT rev (3m)-0.08%
EPS NQ rev (1m)0.12%
EPS NQ rev (3m)-3.58%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)6.05%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)2.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.34 | ||
| Fwd PE | 9.28 | ||
| P/S | 2.19 | ||
| P/FCF | 11.88 | ||
| P/OCF | 10.36 | ||
| P/B | 1.24 | ||
| P/tB | 13.11 | ||
| EV/EBITDA | 7.38 |
EPS(TTM)16.01
EY10.7%
EPS(NY)16.13
Fwd EY10.78%
FCF(TTM)12.6
FCFY8.42%
OCF(TTM)14.44
OCFY9.65%
SpS68.19
BVpS120.28
TBVpS11.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROCE | 10.87% | ||
| ROIC | 9.52% | ||
| ROICexc | 10.7% | ||
| ROICexgc | 37.26% | ||
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% | ||
| FCFM | 18.47% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexcg growth 3Y14.15%
ROICexcg growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Debt/EBITDA | 1.81 | ||
| Cap/Depr | 36.28% | ||
| Cap/Sales | 2.7% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 60.86% | ||
| Profit Quality | 120.66% | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 3.11 |
F-Score6
WACC9.19%
ROIC/WACC1.04
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
EPS Next Y-1.72%
EPS Next 2Y-1.05%
EPS Next 3Y0.57%
EPS Next 5Y1.15%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
Revenue Next Year0.4%
Revenue Next 2Y-1.8%
Revenue Next 3Y-1.14%
Revenue Next 5Y-0.44%
EBIT growth 1Y23.31%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y5.8%
FCF growth 1Y64.41%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y48.2%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%